UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005275
Receipt number R000006234
Scientific Title Effect of cefepime (CFPM) or meropenem (MEPM) for febrile neutropenia patients with lung cancer. Randomized phase II study.
Date of disclosure of the study information 2011/03/18
Last modified on 2013/03/26 14:02:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of cefepime (CFPM) or meropenem (MEPM) for febrile neutropenia patients with lung cancer. Randomized phase II study.

Acronym

Febrile neutropenia patients with lung cancer. CFPM vs MEPM

Scientific Title

Effect of cefepime (CFPM) or meropenem (MEPM) for febrile neutropenia patients with lung cancer. Randomized phase II study.

Scientific Title:Acronym

Febrile neutropenia patients with lung cancer. CFPM vs MEPM

Region

Japan


Condition

Condition

Febrile neutropenia

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to determine the efficacy and safety of cefepime or meropenem for febrile neutropenia in lung cancer patients by prospective randomized study.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Response rate

Key secondary outcomes

Defervescence at 72 hours, 7 days, 14 days
Safety


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking


Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of antibiotics (Cefepime)

Interventions/Control_2

Administration of antibiotics (Meropenem)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Informed consent is obtained
2. Patient who is judged as an appropriate case by the doctor in charge
3. At least 20 years of age
4. Patient who had lung cancer accompanied by chemotherapy-induced neutropenia with a polymorphonuclear neutrophil count of <1000/mm3 and a temperature of >= 37.5

Key exclusion criteria

1. Patient who is too severely ill
2. A history of cardiac failure, renal failure, or liver damage.
3. A known history of hypersensitivity to cephalosporins
4. A known history of allergy
5. Patient who demonstrated positive for skin reaction test ( if skin reaction test was done)
6. Patient who is not evaluated for response
7. Pregnant or lactating women.
8. Patient administered with sodium valproate
9. Patients administered with prohibiting medication (such as other antibiotics, gamma-globulin, corticosteroid, furosemide)
10.patient who is judged as an inappropriate case by the doctor in charge

Target sample size

46


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masaki Fujita

Organization

Fukuoka University

Division name

Department of Respiratory Medicine

Zip code


Address

7-45-1 Nanakuma, Jonanku, Fukuoka

TEL

092-801-1011

Email



Public contact

Name of contact person

1st name
Middle name
Last name Junji Uchino

Organization

Fukuoka University

Division name

Department of Respiratory Medicine

Zip code


Address

7-45-1 Nanakuma, Jonanku, Fukuoka

TEL

092-801-1011

Homepage URL


Email

uchino@fukuoka-u.ac.jp


Sponsor or person

Institute

LOGIK(Lung oncology group in Kyushu)

Institute

Department

Personal name



Funding Source

Organization

Clinical Research Support Center Kyushu

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization

JAPAN


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

福岡大学病院(福岡県)
済生会飯塚嘉穂病院(福岡県)
飯塚病院(福岡県)
九州大学(福岡県)
済生会福岡総合病院(福岡県)
産業医科大学(福岡県)
浜の町病院(福岡県)
福岡大学筑紫病院(福岡県)
国立病院機構福岡病院(福岡県)
原三信病院(福岡県)
大分大学(大分県)
熊本大学(熊本県)
健康保険諫早総合病院(長崎県)
長崎大学病院(長崎県)
国立病院機構岩国医療センター(山口県)


Other administrative information

Date of disclosure of the study information

2011 Year 03 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 12 Month 04 Day

Date of IRB


Anticipated trial start date

2011 Year 01 Month 01 Day

Last follow-up date

2013 Year 01 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 03 Month 18 Day

Last modified on

2013 Year 03 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006234